$0.63
-0.01 (-2.17%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ADGM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 1 with posted results
Held by 1 tracked-famous manager (CITADEL ADVISORS LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| VT Cryoablation System Post-Market Clinical Follow-up (PMCF) StudyNCT06384599Primary Performance EndpointOpen-label · Treatment | Not applicable | Not yet recruiting | Device: VT Cryoablation System | Ventricular Tachycardia | 130 | 2027-05-01 | in 254 d | 2026-04-09 |
| Cryoablation for Monomorphic Ventricular Tachycardia (VTS)NCT07650032Primary Safety Endpoint - Freedom from definite or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the ablation procedure.Open-label · Treatment | Not applicable | Recruiting | Device: Ultra Low Temperature Ablation (ULTA) | Ventricular Tachycardia, Sustained, Ventricular Tachycardia, Monomorphic | 100 | 2027-03-31 | in 223 d | 2026-08-12 |
| Cryoablation for Monomorphic Ventricular TachycardiaNCT05675865Primary Safety Endpoint for EFS and Pivotal phases is freedom from definite or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the cryoablation procedure.Open-label · Treatment | Not applicable | Active, not recruiting | Device: cryoablation procedure | Sustained VT | 206 | 2027-01-31 | in 164 d | 2026-08-07 |
| iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) StudyNCT05416086Primary outcome - freedom from AFOpen-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Adagio Medical no longer manufactures the iCLAS Cryoablation System | Device: cryoablation procedure using the iCLAS Cryoablation System | Atrial Fibrillation, Atrial Flutter, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation | 91 | 2025-01-28actual | — | 2026-04-13 |
| Pulsed Field Ablation and Pulsed Field CRyoAbLation in PErsistent AtriaL FibrilLationNCT05408754Primary Endpoint for SafetyRandomized · Open-label · Treatment | Not applicable | Completed | Device: Atrial ablation for subject scheduled for a de novo endocardial ablation of symptomatic, drug-refractory PsAF. | Atrial Fibrillation | 89 | 2024-10-14actual | — | 2026-04-13 |
| Cryoablation for Monomorphic Ventricular Tachycardia (CryoCure-VT)NCT04893317Primary Endpoint for SafetyOpen-label · Treatment | Not applicable | Completed | Device: Ablation in the ventricles with the Adagio Medical VT Cryoablation System | Monomorphic Ventricular Tachycardia | 64 | 2024-06-30actual | — | 2026-03-19 |
| iCLAS™ for Persistent Atrial FibrillationNCT04061603results2026-08-06Analysis of the Proportion of Subjects Who Are Free From Device/Procedure Related Major Adverse Events (MAEs) That Occur Following the Cryoablation ProcedureOpen-label · TreatmentStudy Protocol ↗ | Not applicable | Completed | Device: Adagio AF Cryoablation System (iCLAS™) | Persistent Atrial Fibrillation | 215 | 2023-08-30actual | — | 2026-08-06 |
| Investigation of the Adagio Cryoablation System in Patients With Atrial FibrillationNCT02839304The primary safety endpoint will be determined by evaluating the incidence of procedural adverse events.Open-label · Treatment | Not applicable | Completed | Device: Cryoablation System | Atrial Fibrillation, Atrial Flutter | 80 | 2020-03-31actual | — | 2021-09-20 |
| Prospective, Multicenter, Investigation of the Adagio Cryoablation System in Subjects With Atrial FlutterNCT02355106Safety measured by the percentage of subjects experiencing cardiovascular specific adverse events (CSAE) within thirty 30 days of the ablation procedure.Open-label · Treatment | Not applicable | Completed | Device: PolarStart System | Atrial Flutter | 17 | 2019-05-01actual | — | 2019-05-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19